Evotec subsidiary Just – Evotec Biologics has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilising its molecular design suite of computational technologies, called J.MD. The investment continues the support for selected Gates Foundation grantees to improve the developability and reduce… Read More
Tessera Therapeutics, a biotech developing a new approach to genome engineering, has entered into an agreement with the Bill & Melinda Gates Foundation to jointly fund the company’s in vivo programme for sickle cell disease (SCD). The funding includes an initial investment, with potential total investment of up to $50… Read More
Women’s health biotech Freya Biosciences has received a $10.4 million strategic investment from the Bill & Melinda Gates Foundation with $1.4 million additional financing from current investor Export and Investment Fund of Denmark (EIFO). The funds will be used to develop microbial immunotherapies for the treatment of… Read More
The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation have announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to… Read More
Edinburgh-based PhaSER Biomedical (PhaSER) has received a Bill & Melinda Gates Foundation grant totalling $2.3m to continue its work in accelerating drug discovery and development. PhaSER will provide 8HUM transgenic mouse models, humanised for key pathways involved in the metabolism and disposition of drugs, to all the… Read More
Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, has received a $1.87 million grant from the Bill & Melinda Gates Foundation in support of vaccine development. Naobios will manufacture a human viral challenge agent that will be used to evaluate… Read More
Cyclica has received a grant from the Bill & Melinda Gates Foundation to apply its AI-enabled drug discovery platform to new therapeutic options for multiple low-data biological targets. The end goal is to expand the range of accessible non-hormonal contraceptive choices for women in developing countries. … Read More
